Meridian Wealth Management LLC purchased a new stake in AbbVie Inc. (NYSE:ABBV) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 3,130 shares of the company’s stock, valued at approximately $204,000.

A number of other hedge funds have also modified their holdings of the business. State Street Corp raised its holdings in shares of AbbVie by 2.4% in the 1st quarter. State Street Corp now owns 72,969,530 shares of the company’s stock valued at $4,754,696,000 after purchasing an additional 1,696,042 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of AbbVie by 4.1% in the 1st quarter. Legal & General Group Plc now owns 7,918,192 shares of the company’s stock valued at $515,956,000 after purchasing an additional 312,055 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of AbbVie by 2.6% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 5,136,674 shares of the company’s stock valued at $334,706,000 after purchasing an additional 130,740 shares in the last quarter. Canada Pension Plan Investment Board raised its holdings in shares of AbbVie by 6.5% in the 1st quarter. Canada Pension Plan Investment Board now owns 3,151,990 shares of the company’s stock valued at $205,384,000 after purchasing an additional 193,410 shares in the last quarter. Finally, US Bancorp DE raised its holdings in shares of AbbVie by 0.3% in the 1st quarter. US Bancorp DE now owns 2,947,561 shares of the company’s stock valued at $192,064,000 after purchasing an additional 9,289 shares in the last quarter. 68.29% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Meridian Wealth Management LLC Purchases New Stake in AbbVie Inc. (ABBV)” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.dailypolitical.com/2017/09/13/meridian-wealth-management-llc-purchases-new-stake-in-abbvie-inc-abbv.html.

ABBV has been the topic of a number of analyst reports. Credit Suisse Group restated a “hold” rating and issued a $65.00 price objective on shares of AbbVie in a report on Wednesday, June 7th. BMO Capital Markets reiterated a “market perform” rating and set a $66.00 price target on shares of AbbVie in a research note on Wednesday, May 17th. Zacks Investment Research lowered shares of AbbVie from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. Societe Generale upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Thursday, June 22nd. Finally, Jefferies Group LLC reiterated a “buy” rating on shares of AbbVie in a research note on Friday, May 26th. Seven analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $79.25.

Shares of AbbVie Inc. (ABBV) traded up 0.13% on Wednesday, reaching $87.86. 3,786,299 shares of the company’s stock traded hands. AbbVie Inc. has a 52 week low of $55.06 and a 52 week high of $88.84. The stock has a market capitalization of $140.06 billion, a PE ratio of 21.61 and a beta of 1.48. The company has a 50 day moving average of $73.09 and a 200-day moving average of $68.79.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 28th. The company reported $1.42 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.40 by $0.02. The company had revenue of $6.94 billion for the quarter, compared to analysts’ expectations of $6.93 billion. AbbVie had a net margin of 24.77% and a return on equity of 150.27%. The firm’s revenue was up 7.6% compared to the same quarter last year. During the same period in the prior year, the company earned $1.26 earnings per share. Equities research analysts forecast that AbbVie Inc. will post $5.52 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th will be issued a dividend of $0.64 per share. The ex-dividend date of this dividend is Thursday, October 12th. This represents a $2.56 dividend on an annualized basis and a dividend yield of 2.92%. AbbVie’s dividend payout ratio (DPR) is 62.90%.

In other AbbVie news, Chairman Richard A. Gonzalez sold 193,131 shares of the stock in a transaction on Monday, August 7th. The shares were sold at an average price of $71.00, for a total transaction of $13,712,301.00. Following the sale, the chairman now directly owns 469,623 shares of the company’s stock, valued at $33,343,233. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward J. Rapp bought 4,000 shares of the company’s stock in a transaction on Monday, July 31st. The shares were acquired at an average cost of $70.45 per share, for a total transaction of $281,800.00. Following the completion of the acquisition, the director now directly owns 15,498 shares of the company’s stock, valued at approximately $1,091,834.10. The disclosure for this purchase can be found here. Insiders have sold 373,191 shares of company stock worth $26,598,305 over the last three months. 0.23% of the stock is owned by corporate insiders.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.